Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORIA Study: Vorasidenib in IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma
NCT06969352Active, not recruiting
- Sponsor
- Servier
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vorasidenib in astrocytoma and Oligodendroglioma (OG) (2 arms), sponsored by Servier. Primary endpoint: Primary efficacy endpoint at 6 months. Started Sep 2025; status: active, not recruiting.
02
Drugs
vorasidenib
03
Conditions
astrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT06969352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969352.